Nasus Pharma Ltd. NSRX
2.91 USD -0.01 (-0.34%)
At closeNov 5, 2026, 7:20 PM EST
2.92 +0.01 +0.34%
After hours · Nov 5, 7:20 PM ET
2.75 Day range 3.02
1.98 52-week range 9.50
- YTD
- -68.20%
- 1 year
- -61.46%
- Market cap
- 34.09M
- EPS (ttm)
- -1.20
- YTD return
- -68.20%
- 1-year return
- -61.46%
- Volume
- 33.30K
- Avg volume
- 16.95K
- Open
- 2.87
- Previous close
- 2.92
- Day's range
- 2.75 – 3.02
- 52-week range
- 1.98 – 9.50
6M -0.26 (-8.28%)
Financials — quick view
NSRX Revenue — annual 0
NSRX Net income — annual -5.86M
NSRX EPS — annual -0.72
News
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday 
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7 
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron 
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis 
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference 
Nasus Pharma Announces Transition of Chief Financial Officer 
Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate 
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update 
Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% – Here’s Why 
Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27
Your note
Sign in to keep a note on NSRX — it syncs with the Stock Master app.